Update in the treatment of AL amyloidosis and Monoclonal gammopathies of clinical significance

Speakers: Bertrand Arnulf

Bertrand Arnulf
 

Professor of Clinical Immunology, University Paris Cité
Head of the Immuno-Hematology Department, Hôpital Saint-Louis, AP-HP, Paris, France

Bertrand Arnulf is a leading expert in clinical immunology and hematology, serving as Professor at University Paris Cité and Head of the Immuno-Hematology Department at Hôpital Saint-Louis. His department is nationally recognized for its specialization in monoclonal gammopathies and related disorders, including Multiple Myeloma, Waldenström's Macroglobulinemia, Monoclonal Gammopathies of Clinical Significance (MGCS), and AL Amyloidosis.

He leads the National Reference Center for AL Amyloidosis and other MGCS, playing a pivotal role in advancing diagnosis, treatment, and research in these complex conditions.

Prof. Arnulf is an active board member of the Intergroupe Francophone du Myélome (IFM), where he coordinates the Myeloma section of the DESCAR-T registry and oversees the CAR-T cell therapy program within IFM.

His research, conducted within INSERM UMR 1342 at the Institut de Recherche Saint-Louis, focuses on basic and translational immunology, particularly the development of novel immunotherapies for Multiple Myeloma. He is actively involved in several major CAR-T cell therapy clinical trials and contributes to shaping the future of personalized immunotherapy in hematologic malignancies.